Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.60 +0.11 (+0.21%)
Streaming Delayed Price Updated: 3:35 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Inc. (NASDAQ: AKRO) is a Stock Spotlight on 6/9
Via Investor Brand Network
News headline image
3 Mid Caps You Haven't Heard Of But Need To Know About
Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration. 
Via MarketBeat
News headline image
Analyst Ratings for Akero Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Expectations for Akero Therapeutics's Future ↗
 
Via Benzinga
News headline image
Recap: Akero Therapeutics Q3 Earnings ↗
Akero Therapeutics (NASDAQ:AKRO) reported its Q3 earnings results on Friday, November 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
From Akero Therapeutics
Via GlobeNewswire
News headline image
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the Jefferies Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
News headline image
$9.6M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
From Akero Therapeutics
Via GlobeNewswire
News headline image
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
News headline image
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
From Akero Therapeutics
Via GlobeNewswire
News headline image
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease ↗
The battle pits 89bio and Akero in nonalcoholic steatohepatitis. 
Via Investor's Business Daily
News headline image
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Akero Therapeutics
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗
 
Via Benzinga
News headline image
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
From Akero Therapeutics
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
News headline image
20 Favorite Biotech & Medical Stocks For 2023 ↗
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
News headline image
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program ↗
 
Via Benzinga
News headline image
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
From Akero Therapeutics
Via GlobeNewswire
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks 
From Akero Therapeutics
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via GlobeNewswire
News headline image
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category 
From Akero Therapeutics
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
News headline image
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
News headline image
Biotech Stocks Well-Positioned For The Fourth Quarter ↗
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
News headline image
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
From Akero Therapeutics
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.